A. Romero-López et al. / Steroids 87 (2014) 86–92
87
4.68 (m, 1H, H-3), 5.40 (1H, dd, J = 12 Hz, J = 4 Hz, H-50), 7.15 (d,
2H, J = 8 Hz, H-200 and H-600), 7.22 (t, 1H, J = 8 Hz, H-400), 7.30 (t,
2H, J = 8 Hz, H-300and H-500). 13C NMR (CDCl3) d: 12.2 (C-19), 13.5
(C-18), 20.9 (3-Ac-CH3), 21.4 (N-Ac-CH3), 21.8 (C-11), 24.9 (C-15),
27.3 (C-2), 28.4 (C-6), 29.6 (C-16), 31.8 (C-7), 33.9 (C-4), 35.4 (C-
8), 35.5 (C-10), 36.7 (C-1), 38.4 (C-12), 44.1 (C-13), 44.5 (C-5),
45.9 (C-40), 51.9 (C-17), 54.1 (C-9), 56.0 (C-14), 59.0 (C-50), 73.5
(C-3), 125.2 (C- 200 and 600), 127.3 (C-400), 128.7 (C-300 and 500), 141.9
(C-100), 159.5 (C-30), 168.4 (N-Ac-CO), 170.7 (3-Ac-CO). HRMS-FAB
(m/z): calcd for C32H44N2O3: 504.3352, found 505.3365 [M+1]+.
The product 4b was obtained as a white solid powder; yield 50%;
ꢀ
1653. 1H NMR (CDCl3) d: 0.63 (s, 3H, CH3-18), 0.80 (s, 3H, CH3-
19), 2.01 (s, 3H, 3-Ac-CH3), 2.31 (s, 3H, N-Ac-CH3), 2.74 (dd, 1H,
J = 16 Hz, J = 4 Hz, H-40), 3.26 (dd, 1H, J = 16 Hz, J = 12 Hz, H-40),
4.67 (m, 1H, H-3), 5.40 (1H, dd, J = 12 Hz, J = 4 Hz, H-50), 7.15 (d,
2H, J = 8 Hz, H-200 and 600), 7.23 (t, 1H, J = 8 Hz, H-400), 7.31 (t, 2H,
J = 8 Hz, H-300 and 500). 13C NMR (CDCl3) d: 12.1 (C-19), 13.6 (C-18),
21.0 (3-Ac-CH3), 21.4 (N-Ac-CH3), 21.8 (C-11), 24.2 (C-15), 24.5
(C-2), 27.3 (C-6), 28.4 (C-16), 29.6 (C-7), 31.8 (C-4), 33.9 (C-8),
35.6 (C-10), 36.7 (C-1), 38.6 (C-12), 44.1 (C-13), 44.5 (C-5), 46.2
(C-40), 51.7 (C-17), 54.1 (C-9), 56.1 (C-14), 59.0 (C-50), 73.6 (C-3),
125.2 (C- 200 and 600), 127.3 (C-400), 128.8 (C-300 and 500), 142.2 (C-
100), 159.3 (C-30), 168.5 (N-Ac-CO), 170.7 (3-Ac-CO). HRMS-FAB
(m/z): calcd for C32H44N2O3: 504.3352, found 505.3365 [M+1]+.
R1
O
R2
HN NH2
N
+
-H2O
N
R
R1
R
R2
Scheme 1. General reaction for the formation of pyrazoline.
tated solid was filtered and washed with ethanol (10 mL) to afford
the product 2 or 6 as solid powder.
2.2.1. (21E)-21-Benzyliden-3b-hydroxypregn-20-one 2
mp. 149–152; [
a
]
D
ꢀ17.7° (c 1 CHCl3); IR
mmax: 2928, 2858, 1727,
Colorless solid powder; yield 80%; mp. 110–111 °C; [
a]
D +37.6°
max: 3411, 2926, 1660, 1607. 1H NMR (CDCl3) d:
ꢀ
m
(c 1, CHCl3); IR
0.61 (s, 3H, CH3-18), 0.79 (s, 3H, CH3-19), 2.82 (t, 1H, J = 8.5 Hz,
H-17), 3.55 (m, 1H, H-3), 6.75 (d, 1H, J = 16.0 Hz, H-21), 7.37 (over-
lapping multiplets, 3H, H-30, H-40, H-50), 7.55 (overlapping multi-
plets, 3H, H-20, H-60, H-22). 13C NMR (CDCl3) d: 12.5 (C-18), 13.9
(C-19), 21.5 (C-11), 22.9 (C-15), 24.8 (C-6), 28.8 (C-16), 31.6 (C-
2), 32.3 (C-7), 35.7 (C-10), 35.8 (C-1), 37.2 (C-8), 38.3 (C-4), 39.6
(C-12), 45.0 (C-5), 45.5 (C-13), 54.5 (C-9), 57.1 (C-14), 62.4 (C-
17), 71.20 (C-3), 126.7 (C-21), 128.5 (C-20,60), 129.1 (C-30,50),
130.4 (C-40), 135.0 (C-10), 141.3 (C-22), 200.4 (C-20). HREI: (m/z)
calcd for C28H38O2: 406.2872, found 406.2881.
2.2.2. (16E)-16-Benzyliden-3b-hydroxyl-5a-androstan-17-one 6
Colorless solid powder; yield 98%; mp. 163–165 °C. 1H NMR
(CDCl3) d: 0.86 (s, 3H, CH3-19), 0.95 (s, 3H, CH3-18), 2.40 (m, 1H,
H-15a), 2.86 (dd, 1H, H-15b), 3.59 (m, 1H, H-3), 7.37 (overlapping
multiplets, 4H, H-10, H-40, H-50, H-60), 7.53 (overlapping multiplets,
2H, H-30, H-70). 13C NMR (CDCl3) d: 12.3 (C-19), 14.4 (C-18), 20.5 (C-
11), 28.3 (C-6), 29.3 (C-15), 31.0 (C-7), 31.3 (C-12), 31.6 (C-2), 34.6
(C-4), 35.7 (C-1), 36.8 (C-10), 37.9 (C-8), 44.7 (C-5), 47.5 (C-13),
49.4 (C-14), 54.4 (C-9), 71.1 (C-3), 128.6 (C-40 and C-60), 129.1 (C-
50), 130.2 (C-30 and C-70), 132.9 (C-1), 135.5 (C-20), 136.1 (C-16),
210.0 (C-17). The spectroscopy data of the compound 6 was com-
pared with that reported in the literature [17].
2.3.2. (50R)- and (50S)-17b-(10-Acetyl-50-phenyl-1H-pyrazolin-30-yl)-
5a
-androstan-3b-ol (3a and 4a)
The individual compounds 3b or 4b (100 mg) were dissolved in a
solution (10%) of KOH in methanol (15 ml). The mixture was allowed
to stand at room temperature, and the progress of the reaction was
monitored by TLC. After completion of the transformation, the reac-
tion mixture was diluted with water. The resulting precipitate was
filtered off, washed with water and dried under vacuum to afford
3a as a white solid powder; yield 85%; mp. 239–241 °C; [
a]
D
ꢀ
+0.57° (c 0.1, CHCl3). IR
m
max: 3408, 2920, 2855, 1648. 1H NMR
(CDCl3) d: 0.63 (s, 3H, CH3-18), 0.81 (s, 3H, CH3-19), 2.31 (s, 3H, N-
Ac-CH3), 2.66 (dd, 1H, Jgem = 20 Hz, J4 a-5 = 4 Hz H-40), 3.36 (dd, 1H,
0
0
Jgem = 20 Hz, J4 b-5 = 12 Hz, H-40), 3.59 (m, 1H, H-3), 5.40 (1H, dd,
2.3. General process for the preparation of steroidal pyrazoline
derivatives
0
0
J5 -4 b = 12 Hz, J5 -4 a = 4 Hz, H-50), 7.14 (d, 2H, J = 8 Hz, H-200 and 600),
7.22 (t, 1H, J = 8 Hz, H-400), 7.30 (t, 2H, J = 8 Hz, H-300 and 500). 13C
NMR (CDCl3) d: 12.3 (C-19), 13.3 (C-18), 21.0 (C-11), 21.8 (N-Ac-
CH3), 24.3 (C-15), 24.4 (C-6), 28.5 (C-16), 29.6 (C-2), 31.4 (C-7),
31.9 (C-1), 35.5 (C-10), 35.6 (C-8), 36.9 (C-4), 38.0 (C-12), 38.5 (C-
13), 44.8 (C-5), 45.8 (C-40), 51.9 (C-17), 54.2 (C-9), 56.1 (C-14), 59.0
(C-50), 71.2 (C-3), 125.2 (C- 200 and 600), 127.3 (C-400), 128.7 (C-300 and
500), 141.9 (C-100), 159.5 (C-30), 168.4 (N-Ac-CO). HRMS-FAB
(m/z): calcd for C32H44N2O3: 462.3246, found 462.3219. 4a: white
ꢀ
0
0
0
0
Compounds 2, 6 or 10 (2.4 mmol) were dissolved in 10 ml of
acetic acid and then hydrazine acetate (4.8 mmol) was added.
The mixture was refluxed and monitored by TLC until complete
disappearance of starting material (ꢁ3 h). The product was precip-
itated by pouring the reaction mass into excessive amounts of ice-
cold water. The formed precipitate was filtered, washed with
water, and dried to afford the products 3a, 4a, 7, 12 and 16.
solid powder; yield 90%; mp. 149–152 °C; IR mmax: 3411, 2921, 2854,
2.3.1. (50S)- and (50R)-17b-(10-Acetyl-50-phenyl-1H-pyrazolin-30-yl)-
1644. 1H NMR (CDCl3) d: 0.63 (s, 3H, CH3-18), 0.78 (s, 3H, CH3-19),
2.31 (s, 3H, N-Ac-CH3), 2.71 (dd, 1H, Jgem = 16 Hz, J4 a-5 = 4 Hz, H-40),
0
0
5
a-androstan-3b-yl acetate (3b and 4b)
0
3.26 (dd, 1H, Jgem = 15.6 Hz, J4 b-5 = 12 Hz, H-40), 3.54 (m, 1H, H-3),
0
The mixture of epimers 3a and 4a was dissolved in CH2Cl2
5.40 (1H, dd, J4 b-5 = 12 Hz, J4 a-5 = 4 Hz, H-50), 7.15 (d, 2H, J = 8 Hz,
H-200 and 600), 7.23 (t, 1H, J = 8 Hz, H-400), 7.31 (t, 2H, J = 8 Hz, H-300
and 500). 13C NMR (d, ppm, CDCl3): 12.2 (C-19), 13.5 (C-18), 21.0
(C-11), 21.8 (N-Ac-CH3), 24.2 (C-15), 24.4 (C-6), 28.5 (C-16), 29.6
(C-2), 31.3 (C-7), 31.9 (C-1), 35.4 (C-10), 35.5 (C-8), 36.9 (C-4), 37.9
(C-12), 38.6 (C-13), 44.7 (C-5), 46.1 (C-40), 51.7 (C-17), 54.2 (C-9),
56.1 (C-14), 59.0 (C-50), 71.1 (C-3), 125.2 (C- 200 and 600), 127.3 (C-400),
128.7 (C-300 and 500), 142.2 (C-100), 159.4 (C-30), 168.6 (N-Ac-CO). HREI:
(m/z) calcd for C30H42N2O2: 462.3246, found 462.3219.
0
0
0
0
(5 ml), subsequently acetic anhydride (5 ml) and catalytic amounts
of DMAP were added, the solution was stirred at room temperature
during 15 min. The mixture was then diluted with water and the
organic phase was extracted with CH2Cl2 (50 mL). The residue
was washed with saturated solution of NaHCO3 (3 ꢂ 30 mL), and
water (40 mL). The resulting organic phase was dried over Na2SO4
and concentrated to dryness under vacuum. The acetylated crude
product was purified by column chromatography on silica gel (hex-
ane/EtOAc 8:2), the product 3b was eluted first and then 4b. The
product 3b was obtained as a white solid powder; yield 25%; mp.
ꢀ
184–186 °C; [
a]
+69.3° (c 1.8, CHCl3); IR
m
max: 2928, 2858, 1727,
2.3.3. 310-Acetyl-50-phenyl-40,50-dihydro[1,2]-diazolo[40,30:16,17]-5
a-
androstan-3b-yl acetate 7
D
1653. 1H NMR (CDCl3) d: 0.62 (s, 3H, CH3-18), 0.83 (s, 3H, CH3-
19), 2.02 (s, 3H, 3-Ac-CH3), 2.31 (s, 3H, N-Ac-CH3), 2.62 (dd, 1H,
J = 20 Hz, J = 4 Hz, H-40), 3.36 (dd, 1H, J = 20 Hz, J = 12 Hz, H-40),
White solid powder; yield 70%; mp. 145–148 °C; [
a]D ꢀ1.48° (c
0.1, CHCl3); IR
max: 2929, 2856, 1727, 1652. 1H NMR (CDCl3) d:
ꢀ
m